Huntington’s Disease (HD) is an inherited degenerative brain disorder characterized by motor abnormalities and dementia produced by selective lesions in the cerebral cortex and, in particular, the striatum. There are presently no known conventional therapies available to alleviate HD symptoms or delay HD-associated striatal degeneration.
Cannabinoids possess various properties that make it attractive in the potential treatment of neurodegenerative disorders like Huntington’s disease,[1-3] and cannabinoid administration has shown efficacy in the treatment of HD in preclinical models[4-6] as well as in case studies. As a result, scientists have called for clinical trials evaluating the effect of cannabinoid pharmacology in HD patients.[8-9] To date, however, no controlled human trials exist assessing cannabis for this clinical condition.